Ischemic heart disease in the elderly. Special Conference of the 36th National Congress of the Spanish Society of Cardiology]

In the field of Cardiology, older patients are the most frequently seen in clinical practice. In the USA, 60% of the patients hospitalized with acute myocardial infarction are 65 or older, as are almost 80% of the patients with heart failure. Population in industrialized countries is aging progressively and this fact is particularly pronounced in Spain, where, as calculated, the population pyramid will be inverted in the next 50 years and people over 65 will be a majority group. We know that age is a determinant factor in the prognosis of illness. With age, comorbidity increases, sex distribution changes, mortal complications have a higher incidence, and there are structural and mechanical functional changes. The specific characteristics of this group of patients and their enormous impact in clinical practice have led us to reconsider the medical focus used to approach this very important aspect of public health. Many of the larger randomized clinical trials have included a narrow spectrum of older patients despite the great relevance that the study of this group might have. On the other hand, the extrapolation of the results obtained in younger patients to older patients implies that the average results of the study may be assigned to a heterogeneous population, not taking into consideration the specificities of each subgroup. Therefore, there is a need to create innovative strategies to optimize the results in the older patient group. Even though clinical trials are a very useful tool to establish the effectiveness of a therapy, from a methodological point of view, they should include a higher number of older patients, and the observational studies undertaken with a rigorous methodology should be more frequently used to generate new knowledge and put the established knowledge info practice. Furthermore, observational studies can be particularly important in the development of strategies that allow the translation of information from the clinical trials to daily clinical practice.     

Inflammation, infection and coronary artery disease: myths and realities. Special XXXV Conference of the National Congress of the Spanish Society of Cardiology

In the past decades it has become apparent that inflammation plays a role in atherogenesis and rapid coronary artery disease progression. Active, or vulnerable, atheromatous plaques are responsible for acute coronary events and contain high concentrations of inflammatory cells as well as molecules involved in the inflammatory process, such as cytokines, adhesion molecules and growth factors. From a clinical perspective, early detection of these plaques may prevent the occurrence of serious coronary events. Unfortunately, current diagnostic techniques -i.e. angiography- do not allow the characterization of events taking place in the arterial wall. Therefore, these diagnostic tools cannot identify vulnerable plaques. Recent studies have suggested that markers of systemic inflammation may help in the detection of high risk patients. Although the role of inflammation in the pathogenesis of atherosclerosis is established, it is not known what triggers inflammation in this context. Infectious agents such as viruses and Gram negative bacteria -i.e. Chlamydia pneumoniae- have been postulated to play a role. Several mechanisms, involving inflammation and immunological processes, have been suggested to explain how chronic infections may cause atherosclerosis. Small pilot studies have also been carried out which suggest a causal role of infection in coronary artery disease. These results, however, await confirmation by other large, currently ongoing, studies. The infectious hypothesis of atherosclerosis is still a matter of debate; however, this theory has contributed to the rapid advance of our knowledge regarding the pathogenesis of coronary artery disease in the past few years. Moreover, the notion that coronary artery disease can be considered to be an inflammatory condition in its own right has opened new and challenging avenues for research.     

心血管影像过去、现在与未来

精准治疗离不开精准诊断,现代影像学技术已经不仅只限于诊断,而且还能够在疾病预后判断和危险分层中发挥重要作用。新技术更是层出不穷,基于分子影像学靶向治疗更是独树一帜、前景无限。现阶段了解心血管影像学基本特点、应用价值和检查适应证,是每一个心血管从业人员必备的基本常识。     

Practice guidelines of the Spanish Society of Cardiology. Cardiac and heart-lung transplants

Cardiac transplantation is the only therapy that is able to substantially modify the natural evolution of patients with severe heart failure, along with angiotensin converting enzyme inhibitors. Nevertheless, because of the limited number of donors, its impact is scarce compared to the magnitude of the problem. Up to the end of 1998, 48,541 orthotopic cardiac transplantations and about 2,510 heart and both lung transplantations have been registered throughout the world. In Spain 2,780 procedures have been performed in the last 15 years. The survival expectations for a transplanted patient is 75% after the first year and 60% the following 5 years. The average duration of the graft is 8 years and 6 months. Cardiac transplantation is indicated for young and middle-age patients with irreversible cardiac process in bad clinical condition, with no other possibility of medical or surgical management and with a limited life expectancy. The major debate when choosing this therapy appears with the critical patients, patients older than 65 years, and some patients with systemic diseases. The great demand of transplantation obliges the teams to enlarge the criteria for donors' acceptance. At the same time, the increase of the knowledge about the transmission of some infections, mainly viral, forces to review those criteria day-to-day. The use of different immunosuppressive strategies pursues the control of rejection. The most commonly used is the so-called triple therapy (cyclosporine-azathioprine and steroids). The use of antilymphocytic antibodies such as cytolytic induction treatment is not unanimously accepted. Some of the new immunosuppressive agents such as myphenolate-mofetil and tacrolimus seem to offer advantages mainly due to their greater potency. Since transplantation is a limited procedure, of which its practise has an effect on the whole health system of a country, a perfect planning and adequacy of the Centers is compulsory, as well as the setting-up of clear rules for the use of donors and priority of transplantation. Finally, the patient must be informed clearly and comprehensively at length of the risks, limitations and expectations of these complex procedures.     

Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals

Disclosure of potential conflicts of interest (COIs) is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into the current COI policies and practices among European Society of Cardiology National Cardiovascular Journals, as derived from a cross-sectional survey using a standardized questionnaire, are discussed.     

Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals

Disclosure of potential conflicts of interest (COI) is used by biomedical journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into the current COI policies and practices among European Society of Cardiology National Cardiovascular Journals, as derived from a cross-sectional survey using a standardised questionnaire, are discussed.     

Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals

Disclosure of potential conflicts of interest (COI) is used by biomedical journals to guarantee credibility and transparency of the scientific process. COI disclosure, however, is not systematically nor consistently dealt with by journals. Recent joint editorial efforts paved the way towards the implementation of uniform vehicles for COI disclosure. This paper provides a comprehensive editorial perspective on classical COI-related issues. New insights into current COI policies and practices among European Society of Cardiology national cardiovascular journals, as derived from a cross-sectional survey using a standardised questionnaire, are discussed.